MedPath

Effects of Memantine to improve cognitive disorders caused by ECT in patients with major depressive disorder

Phase 2
Conditions
Major depressive disorder.
Depressive episode
Registration Number
IRCT201506203930N38
Lead Sponsor
Shiraz University of Medical Sciences, Vice Chancellor for Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Aged between 18 to 65, both gender, major depressive dsorder using DSM-IV criteria
Exclusion criteria: serious medical condition, hypothyroidism, bipolar mood disorder, pregnancy

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression Score. Timepoint: Baseline, the last session of ECT and 2 weeks after the last session of ECT. Method of measurement: Minimal status Examination.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath